Bioline Rx Ltd ADR (BLRX) concluded trading on Thursday at a closing price of $0.26, with 30.03 million shares of worth about $7.81 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -51.76% during that period and on Thursday the price saw a gain of about 19.44%. Currently the company’s common shares owned by public are about 89.11M shares, out of which, 88.62M shares are available for trading.
Stock saw a price change of 9.51% in past 5 days and over the past one month there was a price change of -12.29%. Year-to-date (YTD), BLRX shares are showing a performance of 19.44% which decreased to -83.29% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.19 but also hit the highest price of $1.59 during that period. The average intraday trading volume for Bioline Rx Ltd ADR shares is 1.10 million. The stock is currently trading 12.23% above its 20-day simple moving average (SMA20), while that difference is down -23.46% for SMA50 and it goes to -57.26% lower than SMA200.
Bioline Rx Ltd ADR (NASDAQ: BLRX) currently have 89.11M outstanding shares and institutions hold larger chunk of about 3.72% of that.
The stock has a current market capitalization of $22.78M and its 3Y-monthly beta is at 1.46. It has posted earnings per share of -$0.27 in the same period. It has Quick Ratio of 1.37 while making debt-to-equity ratio of 3.48. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BLRX, volatility over the week remained 23.72% while standing at 13.37% over the month.
Stock’s fiscal year EPS is expected to rise by 91.44% while it is estimated to decrease by -8.69% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Maxim Group on May 18, 2017 offering a Buy rating for the stock and assigned a target price range of between $1 and $3 to it. Coverage by Rodman & Renshaw stated Bioline Rx Ltd ADR (BLRX) stock as a Buy in their note to investors on February 13, 2017, suggesting a price target of $3 for the stock. On August 12, 2016, Maxim Group Downgrade their recommendations, while on August 17, 2015, Maxim Group Reiterated their ratings for the stock with a price target of $4. Stock get a Buy rating from ROTH Capital on July 27, 2015.